news
AstraZeneca cell therapy acquisition to advance in vivo therapies
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
List view / Grid view
Drug Development
news
Nanomaterial research potential “game-changer” for drug delivery
The throughput achieved by the researchers exceeded that of other reported methods by orders of magnitude, supporting the advancement of precision nanomaterials.
news
European Commission approves Rytelo for LR- MDS-related anaemia
The European marketing authorisation offers a new treatment option for patients with transfusion-dependent anaemia in lower-risk myelodysplastic syndromes (LR-MDS), who are unresponsive to erythropoiesis-stimulating agents.
whitepaper
Improving Method Transfer Outcomes
14 March 2025 | By
A collaboration with Pfizer to create a tool to ensuring seamless method transfer between labs.
news
NICE recommends innovative endometriosis pill
Approximately 1,000 eligible NHS patients could benefit from the new endometriosis treatment annually.
news
Bristol Myers Squibb to acquire 2seventy bio
The proposed acquisition, worth nearly $300 million, could help to advance cell therapy in the oncology field.
news
Investigational plaque psoriasis treatments show promise in late-stage trials
With the Phase III trials demonstrating sustained skin clearance in plaque psoriasis, this could lead to patients accessing more treatment options to manage the autoimmune inflammatory disease.
webinar
Safety reporting in clinical trials: six core considerations for success
5 March 2025 | By PPD™ clinical research business of Thermo Fisher Scientific
This webinar will provide guidance in navigating the terrain of pharmacovigilance, including regulatory challenges, and gain a deeper understanding of the pivotal role played by safety reporting in clinical research.
news
CHMP meeting highlights – February 2025
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines plus the extension of therapeutic indications for 16 medicines.
whitepaper
Deepening Digitalization in Drug Discovery at PTC Therapeutics
4 March 2025 | By
PTC Therapeutics accelerates drug discovery process by integrating physicochemical property predictions into their Dotmatics ELN.
article
Preparing for a new era in the rare disease sector
To mark Rare Disease Day 2025, EPR interviewed Christina Gkousgkouni, Head of Rare Diseases for Central South Europe, Sanofi.
news
Imaging discovery could accelerate drug development
The organic fluorophore’s super-photostability enables tracking of previously undetectable biological processes hindered with traditional fluorescent dyes.
news
Could novel 3D printing method enhance intestinal drug delivery?
The research suggests that the innovative 3D printing method has “great” potential for personalised treatments of intestinal inflammatory diseases.
news
NICE recommends novel immunotherapy for leukaemia
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).
webinar
Fast tracking clinical success: choosing the right Fill & Finish CDMO
24 February 2025 | By Adragos Pharma
Selecting the right Fill & Finish CDMO can make or break a product’s commercial success. In this webinar, join industry experts to explore key strategies for navigating this crucial stage, ensuring optimal efficiency where it matters most.
